Douglas Dennis, MD
Orthopaedic Surgery · Denver, CONPI 1275524647
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $16,455,032 of the $16,768,906 with a category attached, or 98.1%. Depuy Synthes Products, Inc. accounts for 98.5% of it on its own, with 10 other manufacturers making up the rest. Among orthopaedic surgery clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 258 payments — averaging $64,996 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Depuy Synthes Products, Inc.$16.5M
- Medical Device Business Services, Inc.$151K
- Omnilife Science, Inc$35K
- Johnson & Johnson$34K
- Corin USA$24K
- Merete Technologies, Inc$500
- plus $576 from 5 others
Across 30 payments — averaging $1783.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medical Device Business Services, Inc.$35K
- Corin USA$9K
- Omnilife Science, Inc$9K
Across 6 payments — averaging $118,105 each. An ownership or investment interest held by the physician or an immediate family member.
- Omnilife Science, Inc$709K
What the payments were for
- Royalty or licence$16,455,03298%
- Consulting fees$263,8752%
- Travel & lodging$43,3080%
- Food & beverage$6,5980%
- Education$930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Depuy Synthes Products, Inc. | 101 | $16,524,859 |
| Medical Device Business Services, Inc. | 65 | $150,590 |
| Omnilife Science, Inc | 57 | $34,633 |
| Johnson & Johnson(2 entities) | 16 | $33,964 |
| Corin USA | 12 | $23,784 |
| Merete Technologies, Inc | 1 | $500 |
| Ziehm-orthoscan, Inc.(2 entities) | 2 | $302 |
| BD | 1 | $129 |
| Zimmer Biomet | 1 | $93 |
| Vertex | 1 | $33 |
| Dynasplint Systems Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ATTUNE$16,664,591
- DERMABOND$43,200
- STRATAFIX$43,200
- OMNIBotics 3.0$24,724
- Various Products$1,696
- ACTIS$1,244
- Velys$145
How this compares
$16,768,906 in reported general payments places this provider in the 95th percentile of 383 orthopaedic surgery providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 41 | $427 |
| Amoxicillin | 107 | $187 |
| Clindamycin Hcl | 21 | $93 |
| Meloxicam | 23 | $46 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Denver
- Brian HaasDenver$5.1M
- Charlie YangDenver$3.6M
- Todd MinerDenver$278K
- Benjamin SearsDenver$186K
- Harold HuntDenver$179K
- Wayne GersoffDenver$164K
- Catherine LoganDenver$93K
- David HahnDenver$77K
- Joshua ParryDenver$47K
- Joel MattaVail$21M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.